PURPOSE: To determine overall survival, best response and toxicities in HCC patients previously treated with chemoembolization (TACE+) treated with resin 90Y transarterial radioembolization (TARE) compared to TACE-naive (T-N) participants.MATERIALS AND METHODS: In this prospective, observational study, 262 adult participants with HCC were TACE+ (n=93, 35%) or T-N (n=169, 65%) at 36 centers in the United States. Overall survival (OS) was assessed using Kaplan-Meier analysis from the date of TARE. Best response at six months was evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST). Six-month toxicities were reported using Common Terminology Criteria for Adverse Events v5.RESULTS: Median OS for TACE+ patients was 22.3 months (95% CI: 17.2, Not Reached) and was 21.5 months (95% CI: 14.9, 29.9) for T-N (p=0.6). Six-month +/- 2 week imaging was available in 156/262 (60%) participants. Partial or complete response was seen in 27/55 (49%) of the TACE+ and 65/101 (64%) T-N patients (p=0.2). Six-month toxicities were available in 69/93 (74%) TACE+ and 135/167 (81%) T-N patients. Attributable grade 3 or greater liver function toxicities were similar between groups (all >0.05).CONCLUSION: OS and imaging response at 6 months of TACE+ participants was similar to that of T-N participants with similar toxicities. Radioembolization is an acceptable treatment option for patients with HCC refractory to TACE.
View details for DOI 10.1016/j.jvir.2023.08.039
View details for PubMedID 37657500